Literature DB >> 729628

The comparative bioavailability of Lanoxin tablets and Lanoxicaps with and without sorbitol.

J O'Grady, B F Johnson, C Bye, J French.   

Abstract

(1) The mean cumulative urinary digoxin excretion over 8 days was compared in 8 healthy volunteers after single doses of digoxin administered as 3 Lanoxin tablets of 0.25 mg, 3 digoxin tablets of 0.2 mg, 12 Lanoxicaps without sorbitol of 0.05 mg, 6 Lanoxicaps without sorbitol of 0.1 mg digoxin, 3 Lanoxicaps without sorbitol of 0.2 mg and 3 Lanoxicaps with sorbitol of 0.2 mg. (2) There was no significant difference between the 8 day cumulative urinary excretion for any of the Lanoxicaps treatments. (3) Cumulative urinary excretion after 3 digoxin tablets of 0.2 mg was significantly (P less than 0.05) lower than after all other treatments. (4) Cumulative urinary excretion after 3 Lanoxin tablets of 0.25 mg was not significantly different from that after any of the Lanoxicaps treatments except 0.1 mg Lanoxicaps without sorbitol, it was significantly (P less than 0.05) lower after the latter. (5) Mean urinary excretion of digoxin was 60% of ingested dose for all Lanoxicaps treatments and was significantly (P less than 0.05) higher than the mean value of 50% for both tablet treatments. (6) Enhanced absorption of digoxin from Lanoxicaps was confirmed and shown to be unrelated to the sorbitol content of the capsule shell.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 729628     DOI: 10.1007/bf00611906

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  11 in total

1.  Maximal intestinal absorption of digoxin, and its relation to steady state plasma concentration.

Authors:  B F Johnson; C Bye
Journal:  Br Heart J       Date:  1975-02

2.  A comparison of the bioavailability of digoxin in capsule, tablet, and solution taken orally with intravenous digoxin.

Authors:  P F Binnion
Journal:  J Clin Pharmacol       Date:  1976-10       Impact factor: 3.126

3.  Evaluation of digoxin capsules in outpatients.

Authors:  E M Rodgers; S M Dobbs; W I Kenyon; J W Poston
Journal:  Br Med J       Date:  1977-07-23

4.  Evaluation of digoxin bioavailability in single-dose studies.

Authors:  D J Greenblatt; D W Duhme; J Koch-Weser; T W Smith
Journal:  N Engl J Med       Date:  1973-09-27       Impact factor: 91.245

5.  Pharmacokinetics of digoxin: interpreting bioavailability.

Authors:  N Sanchez; L B Sheiner; H Halkin; K L Melmon
Journal:  Br Med J       Date:  1973-10-20

6.  Greater bioavailability of digoxin solution in capsules. Studies in the postprandial state.

Authors:  J Lindenbaum
Journal:  Clin Pharmacol Ther       Date:  1977-03       Impact factor: 6.875

7.  Superior bioavailability of digoxin solution in capsules.

Authors:  G I Mallis; D H Schmidt; J Lindenbaum
Journal:  Clin Pharmacol Ther       Date:  1975-12       Impact factor: 6.875

8.  The comparability of dosage regimens of Lanoxin tablets and Lanoxicaps.

Authors:  B F Johnson; G Smith; J French
Journal:  Br J Clin Pharmacol       Date:  1977-04       Impact factor: 4.335

9.  A completely absorbed oral preparation of digoxin.

Authors:  B F Johnson; C Bye; G Jones; G A Sabey
Journal:  Clin Pharmacol Ther       Date:  1976-06       Impact factor: 6.875

10.  Digoxin bioavailability: formulations and rates of infusions.

Authors:  F I Marcus; J Dickerson; S Pippin; M Stafford; R Bressler
Journal:  Clin Pharmacol Ther       Date:  1976-09       Impact factor: 6.875

View more
  1 in total

1.  A standard approach to compiling clinical pharmacokinetic data.

Authors:  L B Sheiner; L Z Benet; L A Pagliaro
Journal:  J Pharmacokinet Biopharm       Date:  1981-02
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.